Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 182

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 182
---
 cannot predict with certainty the long-term effects of any potential changes.

The patent protection and patent prosecution for some of our
drug candidates may in the future be dependent on third parties.

While we normally seek to gain the right to fully
prosecute the patent applications relating to our drug candidates, there may be times when certain patents or patent applications relating
to our drug candidates, their compositions, uses or their manufacture may be controlled by our current or future collaboration partners
or licensors. If any of our current or future collaboration partners fail to appropriately or broadly prosecute patent applications or
maintain patent protection of claims covering any of our drug candidates, their compositions, uses or their manufacture, our ability to
develop and commercialize those drug candidates may be adversely affected and we may not be able to prevent competitors from making, using,
importing, offering to sell or selling competing products. In addition, even where we now have the right to control patent prosecution
of patent applications or the maintenance of patents, we have licensed from third parties, presently or in the future, we may still be
adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent
prosecution.

Confidentiality and invention assignment agreements with our
employees, advisors and consultants may not adequately prevent disclosure of trade secrets and protect other proprietary information.

We consider proprietary trade secrets and/or confidential
know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or confidential know-how to protect
our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets and/or confidential
know-how can be difficult to maintain as confidential.

To protect this type of information against disclosure
or appropriation by competitors, our policy is to require our employees, advisors and consultants to enter into confidentiality and invention
assignment agreements with us. However, current or former employees, advisors and consultants may unintentionally or willfully disclose
our confidential information to competitors, and confidentiality and invention assignment agreements may not provide an adequate remedy
in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using
trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality and invention
assignment agreements may vary from jurisdiction to jurisdiction.

Failure to obtain or maintain trade secrets and/or
confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop